Medical Advice — Not Policy — Should Drive Care for Patients with Alzheimer’s and NPS
Alzheimer’s Disease and related Dementias not only rob people of their memories, but it can change their personalities and…
more.
UPDATE: The 18th Annual FDA/ACT-AD Allies Meeting has been rescheduled for Wednesday, January 21, 2026.
The mission of Accelerate Cures/Treatments for All neuroDegenerative Diseases (ACT-AD) is to support accelerating research and approval for transformational therapies to modify the progression, or relieve symptoms, of all dementias.
ACT-AD brings together companies, advocacy groups, and researchers to interact with the FDA outside of an IND to explore challenges and themes in ADRD clinical development. ACT-AD also provides an overview of research priorities for the NIA and coverage and reimbursement issues for new AD medical products. ACT-AD translates complex regulatory issues to a wide range of stakeholders, including patients and caregivers, to create more engagement on issues that would otherwise be restricted to regulators and companies.
Methods
Program objectives are:
- To create a sense of urgency in support of bringing dementia products to market;
- To obtain public and government recognition of dementia as a serious, life-threatening epidemic; and
- To accelerate development of safe and effective disease-modifying and symptomatic therapies in dementia.
FDA/ACT-AD Allies Annual Meeting
Every year the FDA and ACT-AD convene a roundtable meeting to explore the current therapeutic and research landscape for Alzheimer’s disease and related dementias. Sessions address pertinent issues in the field of dementia research and include presentations from NIH/NIA funded investigators and private industry.
The 17th Annual FDA/ACT-AD Allies meeting was held on November 7, 2024 at the Marriott Marquis, 901 Massachusetts Ave., NW, Washington, DC.
UPDATE: The 18th Annual FDA/ACT-AD Allies meeting (originally scheduled for November 5, 2025) has been rescheduled to Wednesday, January 21, 2026. Meeting information has been sent to invitees directly.
Attendance is by invitation only. If you are interested in attending, please email Beth Mathews-Bradshaw, Alliance Vice President of Research and Patient Engagement, [email protected].
Past Meeting Summaries
2024
The 17th Annual FDA/ACT-AD Allies Meeting was held November 7, 2024. Download a PDF summary of the meeting.
2023
The 16th Annual FDA/ACT-AD Allies Meeting was held November 16, 2023. Download a PDF summary of the meeting.
2022
The 15th Annual FDA/ACT-AD Allies Meeting was held November 16, 2022. Download a PDF summary of the meeting.
2019
The 12th Annual FDA/ACT-AD Allies Meeting was held November 2019. Download a PDF summary of the meeting.
Videos
Caring for a Loved One With Alzheimer’s Disease and Neuropsychiatric Symptoms: Anxiety & Depression
Carolyn Clevenger is a geriatric nurse practitioner at Emory University, where she leads the Integrative Memory Care Clinic. Carolyn cares…
more.
Caring for a Loved One With Alzheimer’s Disease and Neuropsychiatric Symptoms: Sleep Disturbances
Carolyn Clevenger is a geriatric nurse practitioner at Emory University, where she leads the Integrative Memory Care Clinic. Carolyn cares…
more.To Learn More
To learn more about ACT-AD and the annual meeting, please email [email protected]; and/or Beth Mathews-Bradshaw, Vice President of Patient Engagement and Research, at bmbrad[email protected].
To learn more about sponsoring ACT-AD, please contact Sarah Delgado, Vice President of Development, at [email protected].